Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy
Status:
Recruiting
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
Multiple system atrophy (MSA) is a fetal, rare neurodegenerative disease presenting with
parksinonism, autonomic dysfunction, and cerebellar ataxia. Numerous anti-parkinsonism agents
have been developed. However, no medication has yet been proven effective for the symptomatic
or even causative treatment in cerebellar ataxia. To our knowledge, cerebellar N-methyl-D-
aspartic acid (NMDA) receptors play a special role in the modulation of motor learning and
coordination. Tllsh2910, a NMDA modulator, has been found to attenuate the ataxic gait in the
mouse model. Here, we designed a large-scale double-blind randomized controlled, cross-over
phase III trial to investigate the efficacy of Tllsh2910 in neurodegenerative ataxic patients
and the association of gut microbiota change.